{
    "clinical_study": {
        "@rank": "36771", 
        "arm_group": [
            {
                "arm_group_label": "GLPG0974", 
                "arm_group_type": "Experimental", 
                "description": "1 capsule of 200 mg GLPG0974 twice daily"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "1 capsule placebo twice daily"
            }
        ], 
        "brief_summary": {
            "textblock": "-  Approximately 45 patients suffering from mild to moderate ulcerative colitis will be\n           examined for any side effects (safety and tolerability) that may occur when taking\n           GLPG0974 or matching placebo (2:1 ratio) for 28 days.\n\n        -  During the course of the study, patients will also be evaluated for improvement of\n           disease activity by different efficacy measures, the amount of GLPG0974 present in the\n           blood determined (PK) and the effects of GLPG0974 on selected biomarkers (PD) in the\n           blood, colon biopsies and faeces will be explored."
        }, 
        "brief_title": "Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Study of GLPG0974 in Subjects With Ulcerative Colitis", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "condition": "Ulcerative Colitis", 
        "condition_browse": {
            "mesh_term": [
                "Colitis", 
                "Colitis, Ulcerative", 
                "Ulcer"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Key Inclusion Criteria:\n\n          -  Men or women between 18 to 75 years of age inclusive, on the day of signing the\n             informed consent with a documented history of UC.\n\n          -  Presence of mild-to-moderately active ulcerative colitis as evidenced by clinical\n             signs and endoscopy.\n\n          -  Medication:  5-ASA.\n\n          -  Absence of infectious colitis.\n\n        Key Exclusion Criteria:\n\n          -  History of sensitivity to any component of the study drug\n\n          -  Any concurrent illness, condition, disability or clinically significant abnormality\n             (including lab tests) that represents a safety risk , may affect the interpretation\n             of data, or may prevent the subject to safely complete the assessments\n\n          -  Positive serology for HIV 1 or 2 or hepatitis B or C, or any history of HIV or\n             hepatitis.\n\n          -  History of active infections requiring intravenous antibiotics within the past four\n             weeks prior to randomization.\n\n          -  History of bowel surgery, or presence or history of intestinal malignancy.\n\n          -  Suspicion of Crohn's disease, indeterminate colitis, microscopic colitis, ischaemic\n             colitis or radiation-induced colitis.\n\n          -  History of lower GI bleeding disorder, other than UC.\n\n          -  A history of significant psychological, neurologic, hepatic, renal, endocrine,\n             cardiovascular, gastrointestinal (other than UC), pulmonary or metabolic disease.\n\n          -  History of tuberculosis (TB) infection.\n\n          -  Treatment with systemic corticosteroids within 1 week prior to randomization.\n\n          -  Treatment with TNF-\u03b1 inhibitors or other biologics within 2 months prior to\n             randomization.\n\n          -  Treatment with immunosuppressants, initiated or changed within 3 months prior to\n             randomization .\n\n          -  Current use of probiotic or prebiotic preparations\n\n          -  Regular daily use of NSAIDs, within 7 days prior to randomization.\n\n          -  Administration of any experimental therapy within 90 days or 5x the half-life.\n\n          -  History of drug or alcohol abuse.\n\n          -  Pregnant or lactating women.\n\n          -  Medical, psychiatric,  cognitive, or other conditions that compromise the subject's\n             ability to complete the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "45", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01829321", 
            "org_study_id": "GLPG0974-CL-201", 
            "secondary_id": "2012-005521-73"
        }, 
        "intervention": [
            {
                "arm_group_label": "GLPG0974", 
                "description": "1 capsule in the morning and 1 capsule in the evening with food during 28 days", 
                "intervention_name": "GLPG0974", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "1 capsule in the morning and 1 capsule in the evening with food during 28 days", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 24, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Bonheiden", 
                        "country": "Belgium"
                    }, 
                    "name": "Imelda"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gent", 
                        "country": "Belgium"
                    }, 
                    "name": "UZ Gent"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kortrijk", 
                        "country": "Belgium"
                    }, 
                    "name": "AZ Groeninge"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leuven", 
                        "country": "Belgium"
                    }, 
                    "name": "UZ Leuven"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hradec Kralove", 
                        "country": "Czech Republic"
                    }, 
                    "name": "Hepato-Gastroenterologie HK, s.r.o."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Olomouc", 
                        "country": "Czech Republic"
                    }, 
                    "name": "Fakuln\u00ed nemocnice Olomouc"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Prague", 
                        "country": "Czech Republic"
                    }, 
                    "name": "Homolka Hospit\u00e1l"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Slany", 
                        "country": "Czech Republic"
                    }, 
                    "name": "Nemocnice Slan\u00fd"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Usti nad Labem", 
                        "country": "Czech Republic"
                    }, 
                    "name": "Krajsk\u00e1 zdravotn\u00ed a.s., Masarykova nemocnice v \u00dast\u00ed nad Labem T. Bati a.s."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Zlin", 
                        "country": "Czech Republic"
                    }, 
                    "name": "Krajsk\u00e1 nemocnice Tom\u00e1\u0161e Bati - Zlin"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Znojmo", 
                        "country": "Czech Republic"
                    }, 
                    "name": "Nemocnice Znojmo"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Riga", 
                        "country": "Latvia"
                    }, 
                    "name": "SIA Gremo\u0161anas slim\u012bbu centrs \"Gastro\""
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Riga", 
                        "country": "Latvia"
                    }, 
                    "name": "Latvijas J\u016bras Medic\u012bnas Centrs"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Riga", 
                        "country": "Latvia"
                    }, 
                    "name": "R\u012bgas slimn\u012bca Bikor Holim"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bratislava", 
                        "country": "Slovakia"
                    }, 
                    "name": "Univerzitn\u00e1 nemocnica Bratislava"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nitra", 
                        "country": "Slovakia"
                    }, 
                    "name": "Fakultn\u00e1 Nemocnica Nitra"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Belgium", 
                "Czech Republic", 
                "Latvia", 
                "Slovakia"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "Exploratory, Phase II, Randomized, Double-blind, Placebo-controlled, Proof-of-Concept Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of GLPG0974 in Subjects With Mild to Moderate Ulcerative Colitis", 
        "overall_official": {
            "affiliation": "Galapagos NV", 
            "last_name": "Fr\u00e9d\u00e9ric Vanhoutte, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "Belgium: Federal Agency for Medicinal Products and Health Products", 
                "Czech Republic: State Institute for Drug Control", 
                "Latvia: State Agency of Medicines", 
                "Slovakia: State Institute for Drug Control"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "To evaluate the safety and tolerability of GLPG0974 in terms of the number of adverse events reported", 
                "measure": "Number of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Screening up to Follow up (14 days after last dosing)"
            }, 
            {
                "description": "To evaluate the safety and tolerability of GLPG0974 in terms of the changes in physical exam measures reported", 
                "measure": "Changes in physical exam measures", 
                "safety_issue": "Yes", 
                "time_frame": "Screening up to Follow up (14 days after last dosing)"
            }, 
            {
                "description": "To evaluate the safety and tolerability of GLPG0974 in terms of the changes in vital signs as measured by heart rate, blood pressure and oral temperature reported", 
                "measure": "Changes in vital signs as measured by heart rate, blood pressure and oral temperature", 
                "safety_issue": "Yes", 
                "time_frame": "Screening up to Follow up (14 days after last dosing)"
            }, 
            {
                "description": "To evaluate the safety and tolerability of GLPG0974 in terms of the changes in 12-lead ECG measures reported", 
                "measure": "Changes in 12-lead ECG measures", 
                "safety_issue": "Yes", 
                "time_frame": "Screening up to Follow up (14 days after last dosing)"
            }, 
            {
                "description": "To evaluate the safety and tolerability of GLPG0974 in terms of changes in blood safety lab parameters reported", 
                "measure": "Changes in blood safety lab parameters", 
                "safety_issue": "Yes", 
                "time_frame": "Screening up to Follow up (14 days after last dosing)"
            }, 
            {
                "description": "To evaluate the safety and tolerability of GLPG0974 in terms of changes in urine safety lab parameters reported", 
                "measure": "Changes in urine safety lab parameters", 
                "safety_issue": "Yes", 
                "time_frame": "Screening up to Follow up (14 days after last dosing)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01829321"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To evaluate the efficacy of GLPG0974 in terms of changes in (partial) Mayo clinical disease activity score reported", 
                "measure": "Changes in (partial) Mayo clinical disease activity score", 
                "safety_issue": "No", 
                "time_frame": "From Day 1 to Day 29"
            }, 
            {
                "description": "To evaluate the efficacy of GLPG0974 in terms of changes in histopathological clinical activity score (Geboes score) in colon biopsies reported", 
                "measure": "Changes in histopathological clinical activity score in colon biopsies", 
                "safety_issue": "No", 
                "time_frame": "Day 1 and Day 29"
            }, 
            {
                "description": "To evaluate the amount of GLPG0974 in plasma over time after multiple oral doses of GLPG0974 - pharmacokinetics (PK) in ulcerative colitis patients", 
                "measure": "The amount of GLPG0974 in plasma over time after multiple oral doses of GLPG0974", 
                "safety_issue": "No", 
                "time_frame": "Day 8, Day 15 and Day 29"
            }, 
            {
                "description": "To evaluate the changes in the levels of calprotectin in faeces over time after multiple oral doses of GLPG0974 - pharmacodynamics (PD) in ulcerative colitis patients", 
                "measure": "Changes in the levels of faecal calprotectin over time after multiple oral doses of GLPG0974", 
                "safety_issue": "No", 
                "time_frame": "Screening up to Day 29"
            }, 
            {
                "description": "To evaluate the changes in the levels of C-reactive protein in serum over time after multiple oral doses of GLPG0974 - pharmacodynamics (PD) in ulcerative colitis patients", 
                "measure": "Changes in the levels of C-reactive protein in serum over time after multiple oral doses of GLPG0974", 
                "safety_issue": "No", 
                "time_frame": "Screening up to Day 29"
            }, 
            {
                "description": "To evaluate the changes in the levels of MPO in colon biopsies over time after multiple oral doses of GLPG0974 - pharmacodynamics (PD) in ulcerative colitis patients", 
                "measure": "Changes in the levels of myeloperoxidase (MPO) in colon biopsies over time after multiple oral doses of GLPG0974", 
                "safety_issue": "No", 
                "time_frame": "Day 1 and Day 29"
            }, 
            {
                "description": "To evaluate the changes in the levels of predominant microbiota in faeces over time after multiple oral doses of GLPG0974 - pharmacodynamics (PD) in ulcerative colitis patients", 
                "measure": "Changes in the levels of predominant microbiota in faeces over time after multiple oral doses of GLPG0974", 
                "safety_issue": "No", 
                "time_frame": "Day 1 and Day 29"
            }, 
            {
                "description": "To evaluate the changes in the levels of predominant microbiota in colon biopsies over time after multiple oral doses of GLPG0974 - pharmacodynamics (PD) in ulcerative colitis patients", 
                "measure": "Changes in the levels of predominant microbiota in colon biopsies over time after multiple oral doses of GLPG0974", 
                "safety_issue": "No", 
                "time_frame": "Day 1 and Day 29"
            }
        ], 
        "source": "Galapagos NV", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Galapagos NV", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}